Trial of NanoDoce Intratumoral Injection in Renal Cell Carcinoma

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

April 30, 2020

Primary Completion Date

June 30, 2022

Study Completion Date

October 31, 2022

Conditions
Renal Cell CarcinomaKidney CancerAdenocarcinoma of KidneyAdenocarcinoma, RenalRenal Cell Cancer
Interventions
DRUG

NanoDoce (sterile nanoparticulate docetaxel) Powder for Suspension

NanoDoce is manufactured using a Precipitation with Compressed Antisolvent (PCA) technique that employs supercritical carbon dioxide and acetone to generate docetaxel nanoparticles within a well-characterized particle-size distribution. Prior to administration, the NanoDoce powder in vial is suspended with a sterile solution of Polysorbate 80 (0.0075% - 0.0375% (w/w))/Ethanol (0.06% - 0.3% (w/w)) in 0.9% Sodium Chloride for injection.

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

US Biotest, Inc.

INDUSTRY

lead

NanOlogy, LLC

INDUSTRY

NCT04260360 - Trial of NanoDoce Intratumoral Injection in Renal Cell Carcinoma | Biotech Hunter | Biotech Hunter